Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-demethyl-8-dimethylamino-flavin-adenine-dinucleotide is a synthetic analog of flavin adenine dinucleotide (FAD), in which the flavin moiety is modified by replacing the methyl group at position 8 with a dimethylamino group. This compound belongs to the class of (3'→5') dinucleotides and has been studied primarily as an experimental molecule. It is structurally related to roseoflavin, an antibiotic riboflavin analog produced by Streptomyces davawensis, and its phosphorylated forms (such as RoFAD) act as antimetabolites that can interfere with flavoenzyme function. The primary mechanism involves acting as a cofactor analog for flavoenzymes, potentially inhibiting their normal activity due to altered redox properties or binding characteristics[1][7][8]. There are no approved therapeutic indications or clinical uses for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-demethyl-8-dimethylamino-flavin-adenine-dinucleotide.